SEATTLE, WA--(MARKET WIRE)--Jul 11, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) today announced the issuance of an additional patent related to the Company’s leading Adeno-Associated Virus (AAV) technology platform. U.S. patent #7,241,447 titled “Adeno-Associated Virus Vectors and Uses Thereof,” was issued to the University of Iowa Research Foundation and is exclusively licensed to Targeted Genetics. The patent covers the use of two AAV vectors to deliver DNA sequences that, once inside a cell, are used to produce a single protein. This approach allows AAV vectors to be used to deliver genes and regulatory sequences that ordinarily would be too large to fit inside a single vector, expanding the potential applications of AAV-based gene delivery.
